Effect of Polyglucosamine on Weight Loss and Metabolic Parameters in Overweight and Obesity: A Systemic Review and Meta-Analysis.
Tariq A AlalwanSana N M BasharatKhawla Fuad AliAbdulla EidClara GasparriVittoria InfantinoMilena A FalivaTariq Abdulkarim AlalwanRoberta CazzolaBenvenuto CestaroMariangela RondanelliPublished in: Nutrients (2020)
The use of dietary supplements for weight loss has gained significant momentum. Polyglucosamine, a chitosan derivative, is a dietary supplement increasingly used for weight loss. In this meta-analysis, we systematically summarized and quantified the key findings of four randomized, placebo-controlled clinical trials examining the effects of polyglucosamine supplementation and caloric restriction, and physical activity on body weight, body mass index (BMI), and waist circumference in subjects with overweight and obesity. The control group was set with a physical activity from 6-7 MET-h/week activity and up to 21 MET-h/week activity with caloric restriction. Compliance in the latter trials was reported via a follow-up questionnaire with the individual participants. The analysis included 399 subjects followed for a period ranging from 12 weeks to one year. Subjects' age ranged from 21-75 years, BMI from 26-45 kg/m2, and all were white European or Caucasian in ethnicity. The meta-analyzed mean differences for random effects showed that polyglucosamine supplementation improves weight loss by -1.78 kg [-2.78, -0.79], BMI by -1.52 kg/m2 [-3.58, 0.54], and improves waist circumference reduction by -1.45 cm [-2.77, -0.12]. In conclusion, the use of polyglucosamine supplementation in conjunction with lifestyle behavioral therapies can be effective for weight reduction. Further studies are needed to examine the long-term effects of polyglucosamine supplementation on weight loss and other metabolic parameters.
Keyphrases
- body mass index
- weight loss
- physical activity
- bariatric surgery
- placebo controlled
- body weight
- weight gain
- roux en y gastric bypass
- gastric bypass
- double blind
- clinical trial
- systematic review
- glycemic control
- phase ii
- phase iii
- drug delivery
- metabolic syndrome
- case control
- type diabetes
- radiation therapy
- cardiovascular disease
- meta analyses
- study protocol
- cross sectional
- skeletal muscle
- depressive symptoms